Global'naya initsiativa po khronicheskoy obstruktivnoy bolezni legkikh 2006: znachenie dlitel'no deystvuyushchikh bronkhodilatatorov
- Authors: Leshchenko I.V1
-
Affiliations:
- ГОУ ВПО Уральская государственная медицинская академия Росздрава, Екатеринбург
- Issue: Vol 9, No 10 (2007)
- Pages: 10-13
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/92471
- ID: 92471
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
I. V Leshchenko
ГОУ ВПО Уральская государственная медицинская академия Росздрава, ЕкатеринбургКурс пульмунологии
References
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, update 2006 (www. goldcopd.com).
- Хроническая обструктивная болезнь легких. (Федеральная программа). Практическое руководство для врачей. Издание 2-е переработанное и дополненное. Под ред. А.Г.Чучалина М., 2004.
- NICE Guideline №12. Chronic Obstructive Pulmonary Disease. National clinical guideline on management of chronic obstructive pul monary disease in adults in primary and sec ondary care. Developed by the National Col laborating Centre for Chronic Conditions. Tho rax 2004; 59 (suppl. 1): 1–232.
- Chronic Obstructive Pulmonary Disease. Guideline ATS, ERS 2004. www.thoracic.org/COPD.
- Сelli B.R, Mac Nee W and committee members. Standards for the diagnosis and treat ment of patients with COPD: a summary of the ATS/ERS-position paper. Eur Respir J 2004; 23 (6): 932–46.
- Halpin D.M.G. Number needed to treat as a measure of treatment effect. Proceeding ATS 2007. San Francisco, May 18–23, 2007.
- Own L.S, Boonyongsunchai P, Webb S et al. Function of pulmonary neuronal m2 mus carinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1320–5.
- Profita M, Giorgi R, Sala A et al. Muscarinic receptors, leukotriene B4 production and neu trophilic inflammation in COPD patients [abstract 264] Eur Respir J 2004; 24 (suppl. 48): 20s.
- Casaburi R, Mahler D.A, Jones P.W et al. A long - term evaluation of once - daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24.
- Donohue J.F, van Noord J.A, Bateman E.D et al. A 6-month, placebo - controlled study com paring lung function and health status changes in COPD patients treated with tiotropium and salmeterol. Chest 2002; 122: 47–55.
- Vincken W, van Noord J.A, Greefhorst A.P.M et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropi um. Eur Respir J 2002; 19: 209–16.
- Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following six months’ treat ment with once - daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.
- Dusser D, Bravo M-L, Iacono P, on Behalf of the MISTRAL. Study Group. Tiotropium reduces COPD exacerbations: the MISTRAL study [abstract 3203]. Eur Respir J 2004; 24 (Suppl. 48): 513s.
- Dusser D, Bravo M-L, Iacono P on Behalf of the MISTRAL. Study Group. Tiotropium reduces health resource utilization associated with COPD exacerbations. Ibit: [abstract 3204].
- Celli B, Zu Wallack R, Wang S. Improvement in resting inspiratory capacity and hyperinfla tion with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.
- O’Donnell D.E, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.
- Chodosh S, Flanders J.S, Kesten S et al. Effec tive delivery of particles with the HandiHaler dry powder inhalation system over a range of Chronic Obstructive Pulmonary Disease Sever ity. J Aerosol Med 2001; 14 (3): 309–15.
- Dahl R, Backer V, Ollgaard B et al. Assess ment of patient performance of the Handi-Haler R compared with the metered dose inhaler four weeks after instruction. Respir Med 2003; 97: 1126–3.
- Rossi A, Kristufec K, Levine B.E et al. Com parison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow - release theophylline in the treatment of COPD. Chest 2002; 121: 1058–69.
- van Noord J.A, de Munck D.A, Bantje T.A et. al. Long - term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878–85.
- Calverley P.M, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the chronic obstructive pulmonary disease: a ran domized controlled trial. Lancet 2003; 361: 449–56.
- Mahler D.A, Wire P, Horstman D et al. Effec tiveness of fluticasone propionate and salme terol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: (8): 1084–1.
- Lyseng-Williamson K.A, Keating G. Inhaled salmeterol/fluticasone propionate combina tion in chronic obstructive pulmonary disease. Am J Respir Med 2002; 1 (4): 273–83.
- Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pul monary disease. Eur Respir J 2003; 21: 74–81.
- Calverley P.M, Anderson J.A, Celli B et al. TORCH investigators. Salmeterol and fluticas one propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356 (8): 775–89.
- Calverley P.M. Pharmacotherapy can pre vent exacerbations of COPD. Proceeding ATS 2007. San Francisco, May 18–23, 2007.
Supplementary files
